- Home
- RPRX
RPRX
Royalty Pharma plc
as 11-26-2025 3:37pm EST
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 16.2B | IPO Year: | 2020 |
| Target Price: | $46.00 | AVG Volume (30 days): | 4.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 1.75 | EPS Growth: | -31.41 |
| 52 Week Low/High: | $24.05 - $41.24 | Next Earning Date: | 11-05-2025 |
| Revenue: | $2,349,844,000 | Revenue Growth: | 3.70% |
| Revenue Growth (this year): | 36.16% | Revenue Growth (next year): | 2.04% |
Stock Insider Trading Activity of Royalty Pharma plc (RPRX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Coyne Terrance P. | RPRX | EVP & CFO | Nov 24 '25 | Sell | $38.31 | 69,582 | $2,682,505.45 | 669,010 | |
| Coyne Terrance P. | RPRX | EVP & CFO | Nov 17 '25 | Sell | $39.30 | 69,594 | $2,735,329.16 | 669,010 |
Latest Royalty Pharma plc News
RPRX Breaking Stock News: Dive into RPRX Ticker-Specific Updates for Smart Investing
Pharmaceutical Technology
3 days ago
Vaximm and BCME link on oral cancer immunotherapy platform
MT Newswires
6 days ago
Royalty Pharma Insider Sold Shares Worth $5,192,656, According to a Recent SEC Filing
MT Newswires
8 days ago
Royalty Pharma Insider Sold Shares Worth $2,735,329, According to a Recent SEC Filing
Simply Wall St.
9 days ago
Royalty Pharma (RPRX): Is the Stock Undervalued After Higher 2025 Revenue Guidance and Major Buyback Completion?
Simply Wall St.
9 days ago
How Analyst Views on Royalty Pharma Are Shifting
StockStory
9 days ago
3 Value Stocks with Warning Signs
StockStory
10 days ago
3 Low-Volatility Stocks We Find Risky
Investor's Business Daily
13 days ago
Eli Lilly Leads Three Stocks Near Buy Points
Compare RPRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RPRX Royalty Pharma plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.